Clinical Connection

The innovative Optum–MinWorx surgical program dramatically reduces total claim costs and claim duration.

In July 2025, the FDA issued a safety alert regarding risks associated with long-term use of opioid analgesics.

In January 2025, Axsome Therapeutics announced FDA approval of Symbravo for treatment of acute migraine.

Climate change poses significant health risks for workers; our programs work together to address their needs.

Our clinical and policy experts can help you navigate the evolving landscape of GLP-1 medications.

Formulary management works with the authorization process to support worker safety and reduce complexity.